Document ID: chunk:federal_register_of_legislation:F2024L00759:reg:9:p1
Version: federal_register_of_legislation:F2024L00759
Segment Type: reg
Provision Reference: reg 9 (pt 1/3)
Character Range: 4137–7528

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting cardiomyopathy or death from cardiomyopathy with the circumstances of a person's relevant service:
(1)          undergoing a course of radiotherapy for cancer, where the heart was in the field of radiation, before the clinical onset or clinical worsening;
(2)          having myocarditis before clinical onset or at the time of clinical worsening;
(3)          having infection with Trypanosoma cruzi (Chagas disease) before clinical onset or clinical worsening;
(4)          having infection with human immunodeficiency virus before clinical onset or clinical worsening;
(5)          having phaeochromocytoma or paraganglioma at the time of clinical onset or clinical worsening;
Note: paraganglioma and phaeochromocytoma are defined in the Schedule 1 – Dictionary.
(6)          having infiltration of the myocardium due to:
(a)          amyloidosis;
(b)          iron overload (haemosiderosis); or
(c)          sarcoidosis;
at the time of the clinical onset or clinical worsening;
Note: iron overload is defined in the Schedule 1 - Dictionary.
(7)          having a primary or metastatic neoplasm infiltrating the myocardium at the time of the clinical onset or clinical worsening;
(8)          having one of the following endocrine disorders:
(a)          acromegaly;
(b)          adrenal insufficiency;
(c)          Cushing syndrome;
(d)          diabetes mellitus;
(e)          hyperthyroidism, including goitre or Graves disease that has resulted in hyperthyroidism;
(f)           hypoparathyroidism;
(g)          hypothyroidism, including Hashimoto thyroiditis that has resulted in hypothyroidism;
(h)          primary hyperaldosteronism; or
(i)            thyrotoxicosis;
at the time of clinical onset or clinical worsening;
Note: acromegaly and primary hyperaldosteronism are defined in the Schedule 1 – Dictionary.
(9)          being obese at the time of clinical onset or clinical worsening;
Note: being obese is defined in the Schedule 1 - Dictionary.
(10)      having a clinically apparent nutritional deficiency involving:
(a)          carnitine;
(b)          niacin (pellagra);
(c)          selenium (Keshan disease); or
(d)          thiamine (wet beriberi);
at the time of clinical onset or clinical worsening;
(11)      having coeliac disease at the time of clinical onset or clinical worsening;
(12)      having acquired generalised lipodystrophy at the time of the clinical onset or clinical worsening;
Note: lipodystrophy is defined in the Schedule 1 – Dictionary.
(13)      having chronic renal failure at the time of clinical onset or clinical worsening as indicated by any of the following:
(a)          a glomerular filtration rate of less than 15 mL/min/1.73 m2 for a period of at least 3 months; or
(b)          undergoing chronic dialysis for renal failure;
(14)      having cirrhosis of the liver before clinical onset or clinical worsening;
(15)      taking one of the following medications within the 3 months before clinical onset or clinical worsening:
(a)          5-fluorouracil (non-topical);
(b)          alemtuzumab;
(c)          amphotericin B;
(d)          anagrelide;
(e)          bevacizumab;
(f)           cisplatin;
(g)          clozapine;
(h)          cobimetinib;
(i)